Drugs / Orebatinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06578546 | Feb 2024 → Feb 2025 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Orebatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06578546 ↗ |
| Route | Oral | “20mg qod, d4-d21, oral” NCT06578546 ↗ |